This review included the monoclonal antibodies cetuximab, panitumumab and nimotuzumab; the small tyrosine kinase molecules erlotinib and gefitinib; the EGF-based cancer vaccine CIMAvax®; and the EGFR-based cancer vaccine HER-1 vaccine, concluding that apparently, there are no deleterious effects of the anti-EGF/EGFR drugs in the wound healing post-operative process. Here, EGF is linked to cancer.